She covers birth control, thyroid and blood pressure drugs, including why tirzepatide and Foundayo users may need backup contraception after dose increases.
Recap by typeshit. Full story at Newswise.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
There's no appeal under the Bridge, but prescribers can resubmit the prior authorization form. The group explains who counts as Part D eligible instead.
A Facebook explainer says that as of October 2026 retatrutide remains an investigational drug, not cleared by the FDA for any indication.
Loading…